ONCE - Spark Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
111.00
+0.19 (+0.17%)
As of 2:07PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close110.81
Open110.74
Bid110.93 x 900
Ask111.06 x 800
Day's Range110.59 - 111.24
52 Week Range34.53 - 114.20
Volume269,971
Avg. Volume536,160
Market Cap4.276B
Beta (3Y Monthly)2.05
PE Ratio (TTM)N/A
EPS (TTM)-6.55
Earnings DateFeb 19, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est105.12
  • Companies to Watch: Roche gets more time for Spark deal, AstraZeneca shows promise in clinical trial, Snap get upgraded
    Yahoo Finance Video

    Companies to Watch: Roche gets more time for Spark deal, AstraZeneca shows promise in clinical trial, Snap get upgraded

    Roche, Spark, AstraZeneca, Snap, Walmart and eBay are the companies to watch.

  • 7 Philadelphia-area companies make Deloitte fastest-growing list
    American City Business Journals

    7 Philadelphia-area companies make Deloitte fastest-growing list

    Seven Philadelphia-area companies made the list of Deloitte’s fastest-growing tech companies.  Deloitte's latestTechnology Fast 500 ranks the fastest-growing technology companies in North America.

  • For the eighth time, Roche extends $4.3B tender offer for Spark Therapeutics
    American City Business Journals

    For the eighth time, Roche extends $4.3B tender offer for Spark Therapeutics

    Roche on Tuesday once again extended its tender offer to Spark Therapeutics shareholders, citing a need to give regulators additional time to review Roche's proposed $4.3 billion acquisition of the Philadelphia gene therapy pioneer. This is the eighth extension of the tender offer deadline. In February, the two companies announced a merger deal under which Roche would pay Spark stockholders $114.50 per share.

  • Will Spark Therapeutics (ONCE) Report Negative Q3 Earnings? What You Should Know
    Zacks

    Will Spark Therapeutics (ONCE) Report Negative Q3 Earnings? What You Should Know

    Spark Therapeutics (ONCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Why Roche's Acquisition Of Spark May Be Complete By Year's End
    Investor's Business Daily

    Why Roche's Acquisition Of Spark May Be Complete By Year's End

    Roche's acquisition of Spark will likely close before year's end, an analyst said after reports suggested U.S. regulators would bless the deal. Next, U.K. regulators will consider the deal.

  • GlobeNewswire

    Spark Therapeutics Wins Prix Galien USA Award for LUXTURNA® (voretigene neparvovec-rzyl) as Best Biotechnology Product

    Spark Therapeutics (ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced that the Galien Foundation has awarded the prestigious 2019 Prix Galien USA Award for Best Biotechnology Product to LUXTURNA® (voretigene neparvovec-rzyl). The award, announced at the Prix Galien USA Awards Ceremony on Oct. 24, 2019 at the American Museum of Natural History in New York City, recognizes the development of the world’s most innovative medicines that help improve the overall human condition. “We are honored that LUXTURNA, the first gene therapy for an inherited disease in the U.S., was awarded the prestigious 2019 Prix Galien USA Award for Best Biotechnology Product,” said Katherine A. High, M.D., president and head of research & development at Spark Therapeutics.

  • FTC staff recommends approval of Roche deal for Spark: report
    Reuters

    FTC staff recommends approval of Roche deal for Spark: report

    The Federal Trade Commission staff reviewing Roche's plan to buy U.S.-based gene therapy specialist Spark Therapeutics for $4.3 billion recommended that the deal be approved without requiring any asset sales, the Capitol Forum reported on Thursday. Basel-based Roche, the biggest maker of cancer drugs, said in February that it would buy the U.S. company, acquiring a portfolio that includes a blindness treatment that has U.S. and European approval and other projects for neurodegenerative disorders like Huntington's disease. One of its projects is a gene therapy treatment for hemophilia.

  • Gene Therapy Stocks Rocket On Rumor Roche Clinched Its Spark Buyout
    Investor's Business Daily

    Gene Therapy Stocks Rocket On Rumor Roche Clinched Its Spark Buyout

    Shares of gene therapy biotech companies launched in high volume in afternoon action Thursday on rumors the U.S. Federal Trade Commission cleared Roche's takeover of Spark Therapeutics.

  • Hedge Funds Have Never Been This Bullish On Spark Therapeutics Inc (ONCE)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Spark Therapeutics Inc (ONCE)

    A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]

  • U.K.’s Competition watchdog opens probe into Roche takeover of Spark Therapeutics
    MarketWatch

    U.K.’s Competition watchdog opens probe into Roche takeover of Spark Therapeutics

    The regulator said it is looking into whether the deal will result in a substantial lessening of competition, and has set Dec. 16 as its deadline to decide whether it will continue the investigation.

  • Roche Posts Solid Sales for First 9 Months of '19, Ups View
    Zacks

    Roche Posts Solid Sales for First 9 Months of '19, Ups View

    Roche (RHHBY) reports strong sales in the first nine months of 2019 and raises guidance.

  • Reuters

    UPDATE 2-Roche lifts 2019 sales view again as Chinese demand soars

    Swiss drugmaker Roche lifted its 2019 sales target on Wednesday for the third time this year, helped by newer medicines and as China bought more cancer drugs to treat a disease blamed for a quarter of the nation's annual deaths. Roche's full-year revenue is now seen growing at a high-single-digit percentage rate, the Basel-based company said, to what would easily top $60 billion. Over a decade, China has gone from Roche's 10th biggest market to its second-largest behind the United States, with 4.5 billion Swiss francs ($4.5 billion) in 2018 sales.

  • Seventh time a charm? Roche extends $4.3B Spark tender offer once again
    American City Business Journals

    Seventh time a charm? Roche extends $4.3B Spark tender offer once again

    Spark, a company spun out of Children’s Hospital of Philadelphia in 2013, went on to become the first company to receive Food and Drug Administration approval for a gene therapy to treat an inherited disease.

  • Roche's (RHHBY) Rituxan Receives FDA Nod for Label Expansion
    Zacks

    Roche's (RHHBY) Rituxan Receives FDA Nod for Label Expansion

    Roche (RHHBY) gets FDA approval for Rituxan to treat children with two rare blood vessel disorders. The company also extends the offer period to acquire Spark Therapeutics.

  • GlobeNewswire

    Paralympic Skier Danelle Umstead Teams Up with Spark Therapeutics to Help People Living with Inherited Retinal Diseases (IRDs) Access Genetic Testing

    Spark Therapeutics (ONCE), a fully-integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced today that it has teamed up with Danelle Umstead – three-time Paralympian and bronze medalist, 53-time world cup medalist, “Dancing with the Stars” contestant, wife and mom who was clinically diagnosed with retinitis pigmentosa (RP), an inherited retinal disease (IRD) eventually leading to complete blindness – to encourage people living with IRDs to pursue genetic testing to uncover the genetic cause of their condition. Danelle is sharing her personal journey and genetic testing experience as part of Eye Want 2 Know®, an initiative aimed at helping people living with IRDs gain more information about their disease through genetic testing.

  • ETFs Poised to Benefit from Gene Editing Revolution
    Zacks

    ETFs Poised to Benefit from Gene Editing Revolution

    Rising investments and growing technological advancement are favoring the genomic editing space. We take a look at a few ETFs that can cash in on this trend.

  • Reuters

    UPDATE 1-Roche CEO touts drugs pipeline, rules out M&A just to boost sales

    Swiss drugmaker Roche sees medicines in its own pipeline driving sales growth over the longer term, Chief Executive Severin Schwan told Reuters on Friday, adding he will not pursue takeovers simply to keep revenue rising. In an interview at Roche's Basel headquarters, Schwan also said ongoing U.S. Federal Trade Commission (FTC) scrutiny of Roche's $4.3 billion takeover of Spark Therapeutics came as a surprise, forcing delays. Roche has twice upgraded 2019 sales forecasts, the latest time to mid- to high-single-digit percentage rate growth, as medicines including Ocrevus for multiple sclerosis and Hemlibra for haemophilia A offset incursions by rivals' copies of its $22 billion-per-year cancer trio Herceptin, Rituxan and Avastin.

  • Roche CEO touts drugs pipeline, rules out M&A just to boost sales
    Reuters

    Roche CEO touts drugs pipeline, rules out M&A just to boost sales

    Swiss drugmaker Roche sees medicines in its own pipeline driving sales growth over the longer term, Chief Executive Severin Schwan told Reuters on Friday, adding he will not pursue takeovers simply to keep revenue rising. In an interview at Roche's Basel headquarters, Schwan also said ongoing U.S. Federal Trade Commission (FTC) scrutiny of Roche's $4.3 billion takeover of Spark Therapeutics came as a surprise, forcing delays. Roche has twice upgraded 2019 sales forecasts, the latest time to mid- to high-single-digit percentage rate growth, as medicines including Ocrevus for multiple sclerosis and Hemlibra for haemophilia A offset incursions by rivals' copies of its $22 billion-per-year cancer trio Herceptin, Rituxan and Avastin.

  • Roche, Spark again extend $4.3 billion takeover offer
    Reuters

    Roche, Spark again extend $4.3 billion takeover offer

    Roche Holding and Spark Therapeutics announced on Tuesday another extension of the Swiss drugmaker's $4.3 billion takeover offer for the U.S. gene therapy specialist as regulatory reviews continue. The offer for Spark shares now runs to Oct. 1, Roche said. Around 24.1% of Spark's outstanding shares had been tendered as of the end of August.

  • GlobeNewswire

    Spark Therapeutics Announces Change of Location for Annual Meeting of Stockholders

    PHILADELPHIA, Aug. 27, 2019 -- Spark Therapeutics (NASDAQ:ONCE), a fully-integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic.